Shi Siyao Group announced on May 13 on the Hong Kong Stock Exchange that the Group's compound electrolyte injection (500ml) has obtained approval from the China National Drug Administration to pass the consistent evaluation of the quality and efficacy of generic drugs. It is the second domestic company to be approved. Compound electrolyte injections are mainly used as a supplementary source of water, electrolytes, and alkalizing agents. Compound electrolyte injections are compatible with blood and blood components, and the same dosing device can be used to be transfused before or after a blood transfusion (that is, as a prefill), added to the blood component being transfused, or as a diluent for blood cells.
石四药集团：复方电解质注射液通过仿制药质量和疗效一致性评价
Shisi Pharmaceutical Group: Compound Electrolyte Injection Passed the Consistent Evaluation of the Quality and Efficacy of Generic Drugs
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.